1) NIH BOS Montelukast trial (LAI): 19 patients enrolled to date. 14 patients have completed the primary endpoint. Interim analysis will be conducted after 20 patients (likely FY 2011) and analysis of immunological endpoints ongoing. 2) FHCRC new onset BOS trial (chair): submitted to NIH IRB (likely open in FY 2011), open at FHCRC. 3) Lung consortium trial: in development. 4) cGVHD myositis study of respiratory muscle: manuscript in submission. (completed, likely published in FY 2011). 5) AI ON CGVHD Natural history study. Manuscript on PFT function equations in submission (likely published in FY 2011).
|Williams, K M; Ostrow, L W; Loeb, D M et al. (2012) Immunohistochemistry of affected tissue may guide cGVHD treatment decisions. Bone Marrow Transplant 47:731-3|
|Norman, B C; Jacobsohn, D A; Williams, K M et al. (2011) Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant 46:1369-73|
|Chien, Jason W; Duncan, Steven; Williams, Kirsten M et al. (2010) Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 16:S106-14|